Louvain, Belgium, October 29, 2018 / PRNewswire / – Oxurion NV (Euronext Brussels: OXUR – previously generally known as ThromboGenics Nevada), a biopharmaceutical firm that develops modern remedies to protect imaginative and prescient within the eyes of sufferers with eye ailments, at the moment introduced the appointment of Adrienne Graves, Ph.D., to its board of administrators. Dr. Graves will substitute Paul howes, who has been a board member since 2014. "I'm honored to be named for the blackboard of administrators in Oxurion, " mentioned Dr. Critical "The corporate has constructed a various...

LocationKit Magazine